Inceptive

The core of Inceptive's business is its AI platform, which designs novel messenger RNA (mRNA) sequences intended to function as therapeutics and vaccines. This technology addresses the vast, often incomprehensible, number of possible mRNA sequences for a single protein, using AI to identify molecules with optimal drug properties. The company's platform is engineered to navigate this complexity, creating and rapidly testing new molecular structures in its wet lab. Inceptive's business model is centered on licensing these uniquely designed and validated mRNA molecules to pharmaceutical companies, which then undertake further development and clinical trials. This approach positions Inceptive as a horizontal service provider for any entity engaged in developing mRNA and, eventually, other RNA-based medicines. A significant partnership with a major European pharmaceutical firm is already underway to develop a new vaccine for an infectious disease.

Financially, Inceptive has demonstrated significant traction, securing a $20 million seed round in 2021, followed by a substantial $100 million Series A funding round in September 2023. This later round was led by high-profile investors including Andreessen Horowitz and NVIDIA's NVentures, more than tripling the company's valuation to over $300 million. The investment from NVIDIA not only provided capital but also granted Inceptive access to crucial cutting-edge computing hardware, a key resource for developing sophisticated AI algorithms. The company's team is a deliberately cultivated mix of machine learning researchers and wet lab biologists, fostering an "antedisciplinary" environment where cross-functional learning is standard practice.